# Chidamide Combined With Brentuximab Vedotin Regimen for CD30+ PTCL Patients

> **NCT07074457** · NA · RECRUITING · sponsor: **The First Affiliated Hospital of Soochow University** · enrollment: 47 (estimated)

## Conditions studied

- CD30+ Peripheral T-cell Lymphoma

## Interventions

- **DRUG:** Induction therapy-3 cycles of BvC (Brentuximab vedotin plus Chidamide)
- **DRUG:** Consolidation therapy- 3 or 6 cycles of BvC(Brentuximab vedotin plus chidamide)
- **DRUG:** Maintenance therapy-chidamide

## Key facts

- **NCT ID:** NCT07074457
- **Lead sponsor:** The First Affiliated Hospital of Soochow University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-01
- **Primary completion:** 2028-08-01
- **Final completion:** 2028-11-01
- **Target enrollment:** 47 (ESTIMATED)
- **Last updated:** 2025-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07074457

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07074457, "Chidamide Combined With Brentuximab Vedotin Regimen for CD30+ PTCL Patients". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07074457. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*